Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Deferred Revenue (2016 - 2018)

ImmunityBio (IBRX) has disclosed Current Deferred Revenue for 5 consecutive years, with $598000.0 as the latest value for Q4 2018.

  • Quarterly Current Deferred Revenue rose 15.0% to $598000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $598000.0 through Dec 2018, up 15.0% year-over-year, with the annual reading at $598000.0 for FY2018, 15.0% up from the prior year.
  • Current Deferred Revenue for Q4 2018 was $598000.0 at ImmunityBio, up from $577000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $598000.0 in Q4 2018, with the low at $5000.0 in Q4 2015.
  • Average Current Deferred Revenue over 5 years is $407538.5, with a median of $501000.0 recorded in 2017.
  • The sharpest move saw Current Deferred Revenue crashed 99.04% in 2015, then surged 3840.0% in 2016.
  • Over 5 years, Current Deferred Revenue stood at $521000.0 in 2014, then plummeted by 99.04% to $5000.0 in 2015, then soared by 3840.0% to $197000.0 in 2016, then soared by 163.96% to $520000.0 in 2017, then increased by 15.0% to $598000.0 in 2018.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $598000.0, $577000.0, and $558000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.